Drug regulator warns about Meropenem, Disodium

It writes to all CDSCO offices and drug association to curb the trend

March 12, 2024 08:55 pm | Updated March 13, 2024 10:04 am IST - NEW DELHI

Photo: X/@CDSCO_INDIA_INF

Photo: X/@CDSCO_INDIA_INF

The Central Drugs Standard Control Organisation (CDSCO) has cautioned against the manufacture and sale of unapproved drugs specifically warning against drugs falling under the category of “New Drugs”.

(For top health news of the day, subscribe to our newsletter Health Matters)

The organisation citing the example of drugs – Meropenem (antibacterial agent) and Disodium EDTA (to treat calcium overload) – noted that they have got information that some manufacturers are involved in manufacturing/marketing of unapproved drugs which CDSCO does not yet approve.

In its communication to all zonal/sub-zonal offices of CDSCO and the Indian Drugs/Pharmaceutical Association forum, it said that no new drug shall be manufactured for sale unless the licensing authority approves it and additionally a person who intends to manufacture a new drug in the form of Active pharmaceutical ingredients (API) or Pharmaceutical formulation – as the case may be for sale or distribution – shall make an application for grant of permission to the central licensing authority as per the specifications.

CDSCO has now directed that all manufacturers be made aware of the two drugs – Meropenem and Disodium EDTA. “The matter should be conveyed to all manufacturers and the product permission granted by these drugs should be cancelled,’’ it noted.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.